Regado Shock Raises Questions for Oligonucleotide Therapeutics Field
RNAi Therapeutics,
Ave biotech investor, morituri te salutant. Last week, aptamer company Regado Biosciences imploded in a spectacular fashion…
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes…
Overview of attention for article published in European Heart Journal, August 2012
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (91st percentile)
-
Good Attention Score compared to outputs of the same age and source (72nd percentile)
Readers on
- mendeley
- 91 Mendeley